熱門資訊> 正文

Eliem Therapeutics GAAP每股收益为-1.81美元

2024-08-15 00:18

Eliem Therapeutics(ELYM) 0

Eliem Therapeutics press release (NASDAQ:ELYM): Q2 GAAP EPS of -$1.81.
Cash and cash equivalents were $223.1 million as of June 30, 2024, as compared to cash, cash equivalents, and marketable securities of $106.8 million as of December 31, 2023.

More on Eliem Therapeutics

Eliem Therapeutics: Year End 2024 MN Data With Further Potential To Unlock Value
Financial information for Eliem Therapeutics

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。